Overview
- Sun Pharma's Q4 FY25 net profit fell 19% year-on-year to Rs 2,153.9 crore, missing analyst expectations.
- Revenue for the quarter rose 8% to Rs 12,958.8 crore, while EBITDA grew 22.4% to Rs 3,715.9 crore, reflecting operational efficiency.
- The company announced a final dividend of Rs 5.50 per share, with July 7, 2025 set as the record date pending shareholder approval.
- Shares fell nearly 5% following the results, as investors reacted to the profit decline and conservative FY26 revenue guidance of mid- to high-single-digit growth.
- Management plans $100 million in FY26 investments for the US launches of Leqselvi and Unloxcyt, aimed at expanding its specialty portfolio despite near-term margin pressures.